The art of targeting cancer therapies: an interview with Professor Paul Workman
This article was originally published in Scrip
Executive Summary
Whilst there have been many successes in Professor Paul Workman's 30-year career in cancer drug development, the past year arguably serves as the greatest testament to the quality of his endeavours. In April, Roche, the large pharma company most focused on cancer drug development, announced that it would pay $175 million to acquire Piramed Pharma, the private UK biotechnology company that he along with three others founded in 2003.